(3 Minutes Read)
In a significant step toward bolstering Algeria’s pharmaceutical independence and healthcare capabilities, a strategic cooperation agreement has been signed between Saidal, Algeria’s leading state-owned pharmaceutical group, and Novo Nordisk Algeria, the local subsidiary of the Danish biopharmaceutical multinational.
This high-impact alliance aims to co-develop the production and distribution of advanced therapeutic molecules, with a primary focus on the latest generation of insulin treatments essential for diabetes care.
This initiative represents a major advancement in Algeria’s efforts to enhance access to high-quality medical treatments for its population. With an estimated 4 million Algerians living with diabetes—1.5 million of whom rely on insulin—the local production of this vital hormone is not only a healthcare imperative but also a matter of national strategic importance.
By launching local manufacturing of modern insulins, Algeria seeks to reduce its dependence on pharmaceutical imports and reinforce its healthcare autonomy. This effort aligns with the government’s broader national pharmaceutical policy, which prioritizes the local production of key medical treatments such as vaccines, oncology drugs, and biologics. In a recent address to the National People’s Assembly, the Minister of Health reiterated the government’s commitment to eliminating bureaucratic bottlenecks, promoting pharmaceutical exports, and supporting innovation through collaborations with universities and biotech start-ups.
The agreement, signed in the presence of executives from both companies, paves the way for the establishment of a fully integrated aseptic production facility in Algeria. Central to the partnership is a robust framework for the transfer of technology and technical know-how from Novo Nordisk to Saidal. This transfer will empower Algeria to meet international standards in the manufacturing of insulin and other cutting-edge treatments, ensuring better accessibility and safety for Algerian patients.
Through the fusion of Novo Nordisk’s global leadership in diabetes research and biotechnology with Saidal’s established infrastructure and deep roots in the national pharmaceutical landscape, the collaboration is expected to significantly expand Algeria’s capacity for local drug production. It also represents a long-term investment in the country’s scientific and industrial ecosystem.
Read Also;
The project will be carried out in close collaboration with the Ministry of Health and the National Health Insurance Fund, underlining a unified national vision for self-sufficiency in critical healthcare products. This initiative not only meets urgent public health needs but also supports Algeria’s broader goal of positioning itself as a regional hub for pharmaceutical innovation and manufacturing.
